Oculogyric Crisis

Oculogyric crisis is an acute dystonic reaction with sustained, involuntary, typically upward deviation of both eyes. It most commonly occurs as an adverse effect of dopamine receptor blocking medications, particularly typical antipsychotics and certain antiemetics.

It is also recognised in specific neurological conditions, including postencephalitic parkinsonism (historically associated with the encephalitis lethargica epidemic). Less commonly, it is a feature of certain genetic dopamine synthesis or metabolism disorders in children.

Prompt recognition and treatment are important. The condition typically causes significant distress and generally responds rapidly and completely to appropriate treatment.

Pathophysiology

• Drug induced oculogyric crisis reflects an acute imbalance between dopaminergic and cholinergic neurotransmission within the basal ganglia. It is precipitated by dopamine receptor blockade from the causative medication.
• This produces sustained, involuntary conjugate eye deviation. Associated dystonic features frequently affect other cranial and, less commonly, axial musculature.
• Risk factors for drug induced oculogyric crisis and other acute dystonic reactions include younger age, male sex and, importantly, recent initiation or dose increase of the causative medication.
• The reaction typically occurs within the first few days of exposure. This distinguishes it from the more chronic, cumulative dose related movement disorders, such as tardive dyskinesia, that can occur with more prolonged antipsychotic exposure.

• The defining feature is sustained, typically bilateral, upward (and sometimes lateral) deviation of the eyes, lasting from minutes to several hours if untreated. It is often accompanied by significant patient distress, anxiety and agitation.
• Associated dystonic features frequently accompany the oculogyric component: blepharospasm, tongue protrusion, jaw opening or clenching, neck extension or torsion (retrocollis) and, less commonly, more generalised dystonic posturing. The oculogyric crisis is one characteristic manifestation of the broader acute dystonic reaction.
• Specifically seek a relevant recent medication history, particularly recent initiation or dose increase of a dopamine receptor blocking agent. These include typical antipsychotics such as haloperidol, and certain antiemetics such as metoclopramide and prochlorperazine. Both antiemetics carry recognised risk given their dopamine antagonist activity.
• Where a drug related cause is not apparent, assess for any relevant underlying neurological condition.
• The episode is typically alarming to observe and distressing for the patient, but is not itself life threatening.
• The distress and anxiety, with the sometimes dramatic appearance, can occasionally be mistaken for a more serious acute neurological event (such as seizure or stroke) if the characteristic features and medication history are not recognised.

• Diagnosis is clinical. It rests on recognising the characteristic sustained ocular deviation, with any associated dystonic features, in the context of a relevant recent causative medication exposure. In the great majority of straightforward presentations, no investigation is needed beyond confirming the medication history.
• Where the diagnosis is uncertain, or there is no clear relevant medication history, pursue further neurological assessment and, where indicated, investigation for an underlying structural, encephalitic or genetic neurological cause.
• This is particularly relevant in children with this pattern and no obvious causative medication exposure. Consider specific genetic dopamine metabolism disorders.
• The episode is generally straightforward to distinguish clinically from seizure activity. The pattern is sustained ocular and dystonic involvement, without the impaired consciousness or generalised convulsive movement typical of a tonic clonic seizure. Careful clinical assessment remains important where the presentation or history is atypical.

• Intravenous or intramuscular anticholinergic medication is the standard, highly effective first line treatment. This is typically procyclidine 5 to 10 mg, or benztropine where available. It produces rapid, often dramatic resolution of the acute dystonic reaction within minutes to a short period after administration.
• Where the causative medication is identified, discontinue it. Where ongoing antipsychotic treatment remains clinically necessary, switch to an alternative agent with lower dystonic reaction risk, such as an atypical antipsychotic with lower dopamine receptor blocking potency. Guide this by the underlying indication for the original medication and specialist psychiatric input where relevant.
• Consider prophylactic anticholinergic medication for patients needing ongoing treatment with a medication carrying significant dystonic reaction risk, particularly those with a prior history of this reaction.
• Routine prophylactic use in all patients started on relevant medications is not generally recommended, given the additional anticholinergic adverse effect burden it would impose more broadly.
• Reassure the patient and, where relevant, family, with clear explanation. Cover the nature of the reaction, its generally rapid and complete response to treatment, and its distinction from a more serious underlying neurological event. This supports management of the significant anxiety and distress the presentation typically generates.
• Where oculogyric crisis occurs in an underlying neurological condition rather than as a drug induced reaction (postencephalitic parkinsonism, or a specific genetic dopamine metabolism disorder in a child), direct management at the underlying condition according to its specific treatment principles.
• Acute oculogyric episodes in these settings are managed symptomatically with the same anticholinergic approach.